NEW YORK – Immune Therapeutics announced on Monday that it plans to acquire development-stage oncology company Aletheia Therapeutics, and the combined entity will focus on advancing precision oncology treatments.
Immune will acquire all outstanding shares of Aletheia in exchange for Immune common stock. Aletheia's management team and select board members will join the leadership of the combined company. The deal is expected to close in the first quarter of 2020.
"With this acquisition, we will be able to develop a diverse platform of therapies that target multiple critical biological pathways that will be designed for an individual's cancer," Immune CEO Michael Handley said in a statement. The company wants to create therapies that will target DNA repair, T-cell activation, metabolic dysfunction, angiogenesis, apoptosis, or inflammation to treat cancer cells.
Aletheia, a privately owned company, claims to use a systems biology approach to target multiple pathways in cancer biology to ensure their therapies can work across many heterogeneous types of cancers. Immune intends to combine its product candidates Lodonal and MENK with Aletheia's immuno-oncology pipeline. Lodonal is an immune modulator based on low-dose naltrexone. It stimulates the immune system to produce more T cells and natural killer cells. MENK, or met-enkephalin, has been shown to regulate the growth of cancer cells.